Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Target, Costco And A Major Healthcare Stock On CNBC's 'Final Trades'

Published 27/03/2024, 12:13
Updated 27/03/2024, 13:40
© Reuters.  Target, Costco And A Major Healthcare Stock On CNBC's 'Final Trades'

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said CVS Health Corporation (NYSE: CVS) came back strong on news about Amazon.com, Inc. (NASDAQ: AMZN) delivering prescriptions.

Amazon.com’s Amazon Pharmacy has launched Same-Day Delivery of prescription medication in New York City and the greater Los Angeles area.

On March 5, CVS Health reaffirmed its earlier issued full-year 2024 GAAP guidance of at least $7.06 per share and adjusted earnings guidance of at least $8.30 per share.

Jason Snipe of Odyssey Capital Advisors said he likes Costco Wholesale Corporation (NASDAQ: COST). The company’s EPS growth was up 19% in the last quarter, he added.

On March 7, Costco reported total revenue of $58.44 billion in the second quarter, which missed a Street consensus estimate of $59.16 billion, according to data from Benzinga Pro. The company reported net sales of $57.33 billion, which were up 5.7% year-over-year. The company said the net sales were impacted by the shift of the fiscal calendar.

Don’t forget to check out our premarket coverage here

Stephanie Link of Hightower named Target Corporation (NYSE: TGT) as her final trade.

On March 5, Target reported fourth-quarter FY23 revenue growth of 1.7% year-on-year to $31.92 billion, beating the analyst consensus estimate of $31.83 billion. Comparable sales declined 4.4% in the fourth quarter, reflecting comparable store sales declines of 5.4% and a comparable digital sales decline of 0.7%.

Price Action:

  • CVS Health shares gained 0.4% to settle at $79.32 on Tuesday.
  • Costco shares rose slightly to close at $730.98 on Tuesday.
  • Target shares slipped to settle at $172.64 during Tuesday’s session.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Image generated using artificial intelligence with Midjourney.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.